Prevalence and incidence of Parkinson's disease and drug-induced parkinsonism in Korea.
Drug-induced parkinsonism
Incidence
Parkinson’s disease
Pharmacoepidemiology
Prevalence
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
22 Oct 2019
22 Oct 2019
Historique:
received:
25
06
2019
accepted:
20
09
2019
entrez:
24
10
2019
pubmed:
24
10
2019
medline:
8
1
2020
Statut:
epublish
Résumé
Parkinson's disease (PD) and drug-induced parkinsonism (DIP) are the major diseases of parkinsonism. To better understand parkinsonism, we aimed to assess the prevalence and incidence of PD and DIP in Korea from 2012 to 2015. We used the Health Insurance Review and Assessment Service database, which covers the entire population in Korea. We used claims during 2011-2015 to assess epidemiology of PD and DIP during 2012-2015. Retrospective cross-sectional study design was employed to assess prevalence, whereas retrospective cohort study design was used to determine incidence. Patients with at least one claim with ICD-10 G20 and who received antiparkinsonian drugs for at least 60 days were classified as having PD. We excluded patients with antiparkinsonian drugs that can be used for indications other than PD. Patients with at least one claim with ICD-10 G211 or G251 during the prescription period of drugs that are frequently related with DIP were classified as having DIP. Incident cases had a disease-free period of 1 year before diagnosis. To evaluate the significance of changes in the prevalence or incidence over time, Poisson regression was used to determine p for trend. The prevalence of PD increased from 156.9 per 100,000 persons in 2012 to 181.3 per 100,000 persons in 2015 (p for trend< 0.0001). The incidence of PD decreased steadily from 35.4 per 100,000 person-years in 2012 to 33.3 per 100,000 person-years in 2015 (p for trend< 0.0001). The prevalence of DIP increased from 7.3 per 100,000 persons in 2012 to 15.4 per 100,000 persons in 2015 (p for trend< 0.0001) and the incidence of DIP increased from 7.1 per 100,000 person-years in 2012 to 13.9 per 100,000 person-years in 2015 (p for trend< 0.0001). Our study suggests that the incidence of PD has gradually decreased whereas, the incidence of DIP increased from 2012 to 2015. Further studies are warranted to examine possible causes of increased DIP incidence in order to develop management strategy for parkinsonism.
Sections du résumé
BACKGROUND
BACKGROUND
Parkinson's disease (PD) and drug-induced parkinsonism (DIP) are the major diseases of parkinsonism. To better understand parkinsonism, we aimed to assess the prevalence and incidence of PD and DIP in Korea from 2012 to 2015.
METHODS
METHODS
We used the Health Insurance Review and Assessment Service database, which covers the entire population in Korea. We used claims during 2011-2015 to assess epidemiology of PD and DIP during 2012-2015. Retrospective cross-sectional study design was employed to assess prevalence, whereas retrospective cohort study design was used to determine incidence. Patients with at least one claim with ICD-10 G20 and who received antiparkinsonian drugs for at least 60 days were classified as having PD. We excluded patients with antiparkinsonian drugs that can be used for indications other than PD. Patients with at least one claim with ICD-10 G211 or G251 during the prescription period of drugs that are frequently related with DIP were classified as having DIP. Incident cases had a disease-free period of 1 year before diagnosis. To evaluate the significance of changes in the prevalence or incidence over time, Poisson regression was used to determine p for trend.
RESULTS
RESULTS
The prevalence of PD increased from 156.9 per 100,000 persons in 2012 to 181.3 per 100,000 persons in 2015 (p for trend< 0.0001). The incidence of PD decreased steadily from 35.4 per 100,000 person-years in 2012 to 33.3 per 100,000 person-years in 2015 (p for trend< 0.0001). The prevalence of DIP increased from 7.3 per 100,000 persons in 2012 to 15.4 per 100,000 persons in 2015 (p for trend< 0.0001) and the incidence of DIP increased from 7.1 per 100,000 person-years in 2012 to 13.9 per 100,000 person-years in 2015 (p for trend< 0.0001).
CONCLUSIONS
CONCLUSIONS
Our study suggests that the incidence of PD has gradually decreased whereas, the incidence of DIP increased from 2012 to 2015. Further studies are warranted to examine possible causes of increased DIP incidence in order to develop management strategy for parkinsonism.
Identifiants
pubmed: 31640652
doi: 10.1186/s12889-019-7664-6
pii: 10.1186/s12889-019-7664-6
pmc: PMC6805681
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1328Subventions
Organisme : National Research Foundation of Korea
ID : NRF-2016R1C1B1009198
Références
Neurology. 2004 Mar 9;62(5):734-41
pubmed: 15007123
J Clin Neurol. 2012 Mar;8(1):15-21
pubmed: 22523509
Arch Intern Med. 2005 Sep 12;165(16):1882-8
pubmed: 16157833
Arch Neurol. 1983 Mar;40(3):151-4
pubmed: 6830454
Mov Disord. 2014 Nov;29(13):1583-90
pubmed: 24976103
J Korean Med Sci. 2017 May;32(5):718-728
pubmed: 28378543
BMJ Open. 2014 Dec 18;4(12):e006135
pubmed: 25524544
Chin Med J (Engl). 1991 Nov;104(11):960-4
pubmed: 1800040
Lancet Neurol. 2016 Nov;15(12):1257-1272
pubmed: 27751556
Am J Epidemiol. 2003 Jun 1;157(11):1015-22
pubmed: 12777365
J Epidemiol. 2009;19(6):281-93
pubmed: 19801887
J Formos Med Assoc. 2016 Jul;115(7):531-8
pubmed: 26123636
Parkinsonism Relat Disord. 2003 Aug;9 Suppl 2:S99-104
pubmed: 12915074
J Parkinsons Dis. 2011;1(1):35-47
pubmed: 23939255
Expert Opin Drug Saf. 2013 Jul;12(4):487-96
pubmed: 23540800
Mov Disord. 2017 Feb;32(2):227-234
pubmed: 27779780
Mov Disord. 2009 Nov 15;24(15):2249-53
pubmed: 19795476
Psychiatr Serv. 2004 Jun;55(6):691-7
pubmed: 15175468
Eur J Neurol. 2012 Aug;19(8):1108-13
pubmed: 22390275
Mov Disord. 2010 Jun 15;25(8):1053-60
pubmed: 20222132
Parkinsons Dis. 2016;2016:8756359
pubmed: 26904358
Acta Neurol Scand. 2017 Nov;136(5):386-392
pubmed: 27726128
NPJ Parkinsons Dis. 2018 Jul 10;4:21
pubmed: 30003140